Anti-PM-Scl antibodies-positive patients encompass three different groups with distinct prognoses.
Breillat P, Mariampillai K, Legendre P, Martins P, Dunogue B, Charuel JL, Miyara M, Goulvestre C, Paule R, Vanquaethem H, Ackermann F, Benveniste O, Nunes H, Mouthon L, Allenbach Y, Uzunhan Y.
Breillat P, et al. Among authors: vanquaethem h.
Rheumatology (Oxford). 2023 Apr 3;62(4):1467-1475. doi: 10.1093/rheumatology/keac508.
Rheumatology (Oxford). 2023.
PMID: 36063462